Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTBhsp70-scFv(MSLN) fusion protein
- Development stage
- Preclinical
- Lead developer
- Massachusetts General Hospital
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
MTBhsp70-scFv(MSLN) fusion protein is a recombinant biologic immunotherapy designed to target mesothelin-expressing tumors while simultaneously providing a potent immune-activating adjuvant. It consists of a single-chain variable fragment (scFv) specific for mesothelin (MSLN) linked to the Mycobacterium tuberculosis heat shock protein 70 (MTBHsp70). The scFv component directs the protein to MSLN-overexpressing cells, such as those in ovarian cancer and mesothelioma, while the MTBHsp70 component acts as an adjuvant by binding to CD40 on antigen-presenting cells (APCs). This interaction triggers dendritic cell activation, enhances antigen cross-presentation, and stimulates robust CD8+ T-cell and NK-cell mediated anti-tumor responses. Developed primarily in academic settings, it has demonstrated efficacy in preclinical murine models by delaying tumor onset and improving survival.
- Other names
- MTBhsp70-scFv(MSLN) fusion proteinmesothelin-targeted MTBhsp70 fusion protein
02
Targets
TLR4 (Toll-like receptor 4)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)MesothelinLRP1 (Low-density lipoprotein receptor-related protein 1)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on MTBhsp70-scFv(MSLN) fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTBhsp70-scFv(MSLN) fusion protein.